The DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.
The CORE Diabetes Model: Projecting Long-term Clinical Outcomes, Costs and Costeffectiveness of Interventions in Diabetes Mellitus (Types 1 and 2) to Support Clinical and Reimbursement Decision-making
Open accessAbstract
OBJECTIVES: We have developed an Internet-based, interactive computer model to determine the long-term health outcomes and economic consequences of implementing different treatment policies or interventions in type 1 and type 2 diabetes mellitus. The model projects outcomes for populations, taking into account baseline cohort characteristics and past history of complications, current and future diabetes management and concomitant medications, screening strategies and changes in physiological parameters over time. The development of complications, life expectancy, quality-adjusted life expectancy and total costs within populations can be calculated. METHODS: The model is based on a series of sub-models that simulate important complications of diabetes (cardiovascular disease, eye disease, hypoglycaemia, nephropathy, neuropathy, foot ulcer, amputation, stroke, ketoacidosis, lactic acidosis and mortality). Each sub-model is a Markov model using Monte Carlo simulation incorporating time, state, time-in state, and diabetes type-dependent probabilities derived from published sources. Analyses can be performed on cohorts with type 1 or type 2 diabetes. Cohorts, defined in terms of age, gender, baseline risk factors and pre-existing complications, can be modified or new cohorts defined by the user. Economic and clinical data in the model can be edited, thus ensuring adaptability by allowing the inclusion of new data as they become available; creation of country- or provider-specific versions of the model; and allowing the investigation of new hypotheses. CONCLUSIONS: The CORE Diabetes Model allows the calculation of long-term outcomes, based on the best data currently available. Diabetes management strategies can be compared in different patient populations in a variety of realistic clinical settings, allowing the identification of efficient diabetes management strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059 · cited 3×
“Risk adjustment for patients with type 2 diabetes is based on data from the UKPDS and is the same for first and recurrent cataracts 53 .”
BackgroundMethodCost-Effectiveness in Health and Medicine
(1996) · doi:10.1093/oso/9780195108248.001.0001 · Cited by 7,193
Global Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projections
King, H., Aubert, R. E., & Herman, W. H. (1998) · Diabetes Care · doi:10.2337/diacare.21.9.1414 · Cited by 6,311
Stearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 6,090
Global and societal implications of the diabetes epidemic
Zimmet, P., Alberti, K. G. M. M., & Shaw, J. (2001) · Nature · doi:10.1038/414782a · Cited by 5,883
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394 · cited 1×
“85 Probabilities for the onset of microalbum-inuria, progression to gross proteinuria and progression to ESRD are different for patients receiving and not receiving ACEI treatment in the CORE Diabetes Model 84–86 .”
BackgroundWolfe, R. A., Ashby, V. B., Milford, E. L., Ojo, A. O., Ettenger, R. E., Agodoa, L. Y. C., Held, P. J., & Port, F. K. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912023412303 · Cited by 5,371
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
Harris, M. I., Flegal, K. M., Cowie, C. C., Eberhardt, M. S., Goldstein, D. E., Little, R. R., Wiedmeyer, H.-M., & Byrd-Holt, D. D. (1998) · Diabetes Care · doi:10.2337/diacare.21.4.518 · Cited by 2,703
Markov Models in Medical Decision Making: A Practical Guide
Sonnenberg, F. A., & Beck, J. R. (1993) · Medical Decision Making · doi:10.1177/0272989x9301300409 · Cited by 2,419
Long-term trends in the incidence of and survival with heart failure
Levy, D., Kenchaiah, S., Larson, M. G., Benjamin, E. J., Kupka, M. J., Ho, K. K. L., Murabito, J. M., & Vasan, R. S. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020265 · Cited by 2,152 · cited 1×
“These data are comparable to survival curves published by Levy et al. in 2002 52 .”
ResultAdler, A. I. (2000) · BMJ · doi:10.1136/bmj.321.7258.412 · Cited by 2,133
(2000) · PubMed · Cited by 2,095
Amos, A. F., McCarty, D. J., & Zimmet, P. (1997) · Diabetic Medicine · doi:10.1002/(sici)1096-9136(199712)14:5+<s7::aid-dia522>3.0.co;2-r · Cited by 1,882
Survival after the onset of congestive heart failure in Framingham Heart Study subjects.
Ho, K. K., Anderson, K. M., Kannel, W. B., Grossman, W., & Levy, D. (1993) · Circulation · doi:10.1161/01.cir.88.1.107 · Cited by 1,869
Probability of stroke: a risk profile from the Framingham Study.
Wolf, P. A., D'Agostino, R. B., Belanger, A. J., & Kannel, W. B. (1991) · Stroke · doi:10.1161/01.str.22.3.312 · Cited by 1,782 · cited 1×
“Calculations using the Framingham risk functions are based on a proportional hazard regression model published by Wolf et al . which estimates the probability of stroke for patients between the ages of 55 and 84 years with no history of stroke 55 .”
MethodMann, J. F. E., Gerstein, H. C., Pogue, J., Bosch, J., Yusuf, S., & for the HOPE Investigators (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-8-200104170-00007 · Cited by 1,372
Malmberg, K. (1997) · BMJ · doi:10.1136/bmj.314.7093.1512 · Cited by 1,286
Weinstein, M. C., O'Brien, B., Hornberger, J., Jackson, J., Johannesson, M., McCabe, C., & Luce, B. R. (2003) · Value in Health · doi:10.1046/j.1524-4733.2003.00234.x · Cited by 1,172
The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56)
STEVENS, R. J., KOTHARI, V., ADLER, A. I., & STRATTON, I. M. (2001) · Clinical Science · doi:10.1042/cs20000335 · Cited by 1,084 · cited 1×
“The risk model from the UKPDS risk engine is diabetes-specific and takes into account HbA 1c , SBP, lipid levels (total cholesterol to HDL ratio), age, sex, smoking status, race, and time since diagnosis of diabetes to calculate the probability of the first MI 44 .”
MethodThe Pathogenesis of Insulin-Dependent Diabetes Mellitus
Epstein, F. H., Atkinson, M. A., & Maclaren, N. K. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411243312107 · Cited by 1,078
Stratton, I. M., Kohner, E. M., Aldington, S. J., Turner, R. C., Holman, R. R., Manley, S. E., & Matthews, D. R. (2001) · Diabetologia · doi:10.1007/s001250051594 · Cited by 1,019 · cited 3×
“For type 2 diabetes patients, risk multipliers for HbA 1c adjustment are taken from the UKPDS 50 publication 62 and for SBP are based on UKPDS 36 64 .”
MethodProbabilistic Sensitivity Analysis Using Monte Carlo Simulation: A Practical Approach
Doubilet, P., Begg, C. B., Weinstein, M. C., Braun, P., & McNeil, B. J. (1985) · Medical Decision Making · doi:10.1177/0272989x8500500205 · Cited by 860 · cited 1×
“36,37 .”
Ravid, M., Savin, H., Jutrin, I., Bental, T., Katz, B., & Lishner, M. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-118-8-199304150-00001 · Cited by 775
Hypoglycemia in the Diabetes Control and Complications Trial
The Diabetes Control and Complications Trial Research Group (1997) · Diabetes · doi:10.2337/diab.46.2.271 · Cited by 746
Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes
Chaturvedi, N., Sjolie, A.-K., Stephenson, J. M., Abrahamian, H., Keipes, M., Castellarin, A., Rogulja-Pepeonik, Z., & Fuller, J. H. (1998) · The Lancet · doi:10.1016/s0140-6736(97)06209-0 · Cited by 743
Intermittent Claudication: A Risk Profile From The Framingham Heart Study
Murabito, J. M., D’Agostino, R. B., Silbershatz, H., & Wilson, P. W. F. (1997) · Circulation · doi:10.1161/01.cir.96.1.44 · Cited by 696
The Diabetes Control and Complications (DCCT) Research Group (1995) · Kidney International · doi:10.1038/ki.1995.236 · Cited by 694
One Thousand Health-Related Quality-of-Life Estimates
Tengs, T. O., & Wallace, A. (2000) · Medical Care · doi:10.1097/00005650-200006000-00004 · Cited by 662
Natural History of Peripheral Neuropathy in Patients with Non-Insulin-Dependent Diabetes Mellitus
Partanen, J., Niskanen, L., Lehtinen, J., Mervaala, E., Siitonen, O., & Uusitupa, M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199507133330203 · Cited by 656
Primary and subsequent coronary risk appraisal: New results from the Framingham study
D'Agostino, R. B., Russell, M. W., Huse, D. M., Ellison, R. C., Silbershatz, H., Wilson, P. W. F., & Hartz, S. C. (2000) · American Heart Journal · doi:10.1016/s0002-8703(00)90236-9 · Cited by 589
Estimating Utility Values for Health States of Type 2 Diabetic Patients Using the EQ-5D (UKPDS 62)
Clarke, P., Gray, A., & Holman, R. (2002) · Medical Decision Making · doi:10.1177/027298902400448902 · Cited by 515
Valmadrid, C. T., Klein, R., Moss, S. E., & Klein, B. E. K. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.8.1093 · Cited by 472
Klein, R. (1989) · Archives of Ophthalmology · doi:10.1001/archopht.1989.01070010243030 · Cited by 470
Undiagnosed NIDDM: Clinical and Public Health Issues
Harris, M. I. (1993) · Diabetes Care · doi:10.2337/diacare.16.4.642 · Cited by 460
Ravid, M., Brosh, D., Ravid-Safran, D., Levy, Z., & Rachmani, R. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.9.998 · Cited by 452
Profile for Estimating Risk of Heart Failure
Kannel, W. B., D'Agostino, R. B., Silbershatz, H., Belanger, A. J., Wilson, P. W. F., & Levy, D. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.11.1197 · Cited by 422
Kothari (2002) · doi:10.1161/01.str.0000020091.07144.c7 · Cited by 420
Lactic Acidosis in Patients with Diabetes Treated with Metformin
Misbin, R. I., Green, L., Stadel, B. V., Gueriguian, J. L., Gubbi, A., & Fleming, G. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801223380415 · Cited by 403
Petty, G. W., Brown, R. D., Whisnant, J. P., Sicks, J. D., O'Fallon, W. M., & Wiebers, D. O. (1998) · Neurology · doi:10.1212/wnl.50.1.208 · Cited by 393
Health care expenditures for people with diabetes mellitus, 1992.
Rubin, R. J., Altman, W. M., & Mendelson, D. N. (1994) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.78.4.8157701 · Cited by 378
Javitt, J. C., Aiello, L. P., Chiang, Y., Ferris, F. L., Canner, J. K., & Greenfield, S. (1994) · Diabetes Care · doi:10.2337/diacare.17.8.909 · Cited by 364
Insulin prophylaxis in individuals at high risk of type 1 diabetes
Keller, R. J., Jackson, R. A., Eisenbarth, G. S., & Eisenbarth, G. (1993) · The Lancet · doi:10.1016/0140-6736(93)91215-8 · Cited by 298
Validation of the CORE Diabetes Model Against Epidemiological and Clinical Studies
Palmera, A. J., Rozea, S., Valentinea, W. J., Minshallb, M. E., Foosa, V., Luratia, F. M., Lammerta, M., & Spinasc, G. A. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904x2006 · Cited by 284
Malik, R. A., Williamson, S., Abbott, C., Carrington, A. L., Iqbal, J., Schady, W., & Boulton, A. J. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02478-7 · Cited by 284
The Direct Medical Cost of Type 2 Diabetes
Brandle, M., Zhou, H., Smith, B. R. K., Marriott, D., Burke, R., Tabaei, B. P., Brown, M. B., & Herman, W. H. (2003) · Diabetes Care · doi:10.2337/diacare.26.8.2300 · Cited by 269
Diabetic nephropathy in type II diabetes
Ritz, E., & Stefanski, A. (1996) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(96)90538-7 · Cited by 261
Eddy, D. M., & Schlessinger, L. (2003) · Diabetes Care · doi:10.2337/diacare.26.11.3093 · Cited by 260
Model of Complications of NIDDM: I. Model construction and assumptions
Eastman, R. C., Javitt, J. C., Herman, W. H., Dasbach, E. J., Zbrozek, A. S., Dong, F., Manninen, D., Garfield, S. A., Copley-Merriman, C., Maier, W., et al. (1997) · Diabetes Care · doi:10.2337/diacare.20.5.725 · Cited by 258
and the Swedish Childhood Diabetes Study Group, Pundziute-Lyckå, A., Dahlquist, G., Nyström, L., Arnqvist, H., Björk, E., Blohmé, G., Bolinder, J., Eriksson, J., Sundkvist, G., et al. (2002) · Diabetologia · doi:10.1007/s00125-002-0845-2 · Cited by 234
Ragnarson Tennvall, G., & Apelqvist, J. (2001) · Diabetologia · doi:10.1007/s001250100013 · Cited by 229
Developing Guidance for Budget Impact Analysis
Trueman, P., Drummond, M., & Hutton, J. (2001) · PharmacoEconomics · doi:10.2165/00019053-200119060-00001 · Cited by 228
Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme
Herings, R. M. C., de Boer, A., Leufkens, H. G. M., Porsius, A., & Stricker, B. H. C. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91988-0 · Cited by 217
Kshirsagar, A. V., Joy, M. S., Hogan, S. L., Falk, R. J., & Colindres, R. E. (2000) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(00)70018-7 · Cited by 203
Marshall, M. C. (2005) · Postgraduate Medical Journal · doi:10.1136/pgmj.2004.028274 · Cited by 203
Psychological status of diabetic people with or without lower limb disability
Carrington, A. L., Mawdsley, S. K. V., Morley, M., Kincey, J., & Boulton, A. J. M. (1996) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(96)01198-9 · Cited by 201
Drug-Induced Hypoglycemic Coma in 102 Diabetic Patients
Ben-Ami, H., Nagachandran, P., Mendelson, A., & Edoute, Y. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.3.281 · Cited by 201
Probabilistic Analysis of Decision Trees Using Monte Carlo Simulation
Critchfield, G. C., & Willard, K. E. (1986) · Medical Decision Making · doi:10.1177/0272989x8600600205 · Cited by 198
DIABETIC KETOACIDOSIS AND HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC SYNDROME
Delaney, M. F., Zisman, A., & Kettyle, W. M. (2000) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70159-6 · Cited by 187
Qiao, Q. (2002) · European Heart Journal · doi:10.1053/euhj.2001.3113 · Cited by 180
Uusitupa, M., Siitonen, O., Aro, A., & Py�r�l�, K. (1985) · Diabetologia · doi:10.1007/bf00276995 · Cited by 165
Golan, L., Birkmeyer, J. D., & Welch, H. G. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-9-199911020-00005 · Cited by 160
Influence of age on the presentation and outcome of acidotic and hyperosmolar diabetic emergencies
MacIsaac, R. J., Lee, L. Y., McNeil, K. J., Tsalamandris, C., & Jerums, G. (2002) · Internal Medicine Journal · doi:10.1046/j.1445-5994.2002.00255.x · Cited by 138
Weets, I., De Leeuw, I. H., Du Caju, M. V. L., Rooman, R., Keymeulen, B., Mathieu, C., Rottiers, R., Daubresse, J.-C., Rocour-Brumioul, D., Pipeleers, D. G., et al. (2002) · Diabetes Care · doi:10.2337/diacare.25.5.840 · Cited by 137 · cited 1×
“…of type 1 diabetes, which occurs in genetically predisposed persons as a consequence of the immune-mediated destruction of pancreatic islet beta-cells that secrete insulin 19 , is increasing in some European countries and is clinically manifest in younger patient age groups in others 20–23 .”
BackgroundGustafsson, I., Torp-Pedersen, C. T., Køber, L., Gustafsson, F., & Hildebrandt, P. R. (1999) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00146-1 · Cited by 135
The Members of the Italian Group for Pharmacoeconomic Studies, Capri, S., Ceci, A., Terranova, L., Merlo, D. F., & Mantovani, L. G. (2001) · Drug Information Journal · doi:10.1177/009286150103500122 · Cited by 123
O’Brien, J. A., Patrick, A. R., & Caro, J. J. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80122-4 · Cited by 120
Statistical Methodology: III. Receiver Operating Characteristic (ROC) Curves
Grzybowski, M., & Younger, J. G. (1997) · Academic Emergency Medicine · doi:10.1111/j.1553-2712.1997.tb03793.x · Cited by 118
Uncertainty in Decision Models Analyzing Cost-Effectiveness
Hunink, M. G. M., Bult, J. R., de Vries, J. A., & Weinstein, M. C. (1998) · Medical Decision Making · doi:10.1177/0272989x9801800312 · Cited by 111
Morris, A. D., Boyle, D. I., McMahon, A. D., Pearce, H., Evans, J. M. M., Newton, R. W., Jung, R. T., MacDonald, T. M., & The Darts/Memo Collaboration (1997) · Diabetes Care · doi:10.2337/diacare.20.9.1363 · Cited by 109
The global diabetes model: user friendly version 3.0
Brown, J. B., Russell, A., Chan, W., Pedula, K. L., & Aickin, M. G. (2000) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(00)00215-1 · Cited by 108
F�chtenbusch, M., Rabl, W., Grassl, B., Bachmann, W. E., Standl, E., & Ziegler, A. (1998) · Diabetologia · doi:10.1007/s001250050943 · Cited by 106
Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar Nonketotic Syndrome
Umpierrez, G. E., Khajavi, M., & Kitabchi, A. E. (1996) · The American Journal of the Medical Sciences · doi:10.1016/s0002-9629(15)41700-8 · Cited by 102
Predicted Costs and Outcomes From Reduced Vibration Detection in People With Diabetes in the U.S.
Shearer, A. T., Scuffham, P., Gordois, A., & Oglesby, A. K. (2003) · Diabetes Care · doi:10.2337/diacare.26.8.2305 · Cited by 100
Treatment Options for Diabetic Neuropathic Foot Ulcers: A Cost-Effectiveness Analysis
Kantor, J., & Margolis, D. J. (2001) · Dermatologic Surgery · doi:10.1046/j.1524-4725.2001.00280.x · Cited by 93
Metformin and the sulphonylureas: the comparative risk.
Campbell, I. W. (1985) · PubMed · Cited by 85
Post-challenge hyperglycaemia is associated with premature death and macrovascular complications
Qiao, Q., Tuomilehto, J. O., & Borch‐Johnsen, K. (2003) · Diabetologia · doi:10.1007/s00125-002-0932-4 · Cited by 81
Sullivan, S. D., Lyles, A., Luce, B. R., & Grigar, J. (2001) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2001.7.4.272 · Cited by 71
Sprafka, J. M., Virnig, B. A., Shahar, E., & McGovern, P. G. (1994) · Diabetic Medicine · doi:10.1111/j.1464-5491.1994.tb00332.x · Cited by 66
Increasing incidence of childhood-onset type I diabetes in 3 Baltic countries and Finland 1983–1998
Podar, T., Solntsev, A., Karvonen, M., Padaiga, Z., Brigis, G., Urbonaite, B., Viik-Kajander, M., Reunanen, A., & Tuomilehto, J. (2001) · Diabetologia · doi:10.1007/pl00002947 · Cited by 63
Hypoglycemia: A major problem in the management of diabetes in the elderly
Stcepka, M., Rogala, H., & Czyzyk, A. (1993) · Aging Clinical and Experimental Research · doi:10.1007/bf03324137 · Cited by 55
Almbrand, B., Johannesson, M., Sjöstrand, B., Malmberg, K., & Rydén, L. (2000) · European Heart Journal · doi:10.1053/euhj.1999.1859 · Cited by 53
Incidence of and risk factors for cataract among diabetes clinic attenders
Janghorbani, M., Jones, R. B., & Allison, S. P. (2000) · Ophthalmic Epidemiology · doi:10.1076/0928-6586(200003)711-2ft013 · Cited by 42
Outline of a diabetes disease management model: principles and applications
Palmer, A. J., Brandt, A., Gozzoli, V., Weiss, C., Stock, H., & Wenzel, H. (2000) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(00)00216-3 · Cited by 37
Self-citationProphylactic insulin treatment in relatives at high risk for type 1 diabetes
Ziegler, A., Bachmann, W., & Rabl, W. (1993) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610090409 · Cited by 31
Use of pharmacoeconomics in prescribing research. Part 5: modelling - beyond clinical trials
Lang, D., Lopert, R., & Hill, S. R. (2003) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.2003.00458.x · Cited by 24
The large increase in incidence of Type I diabetes mellitus in Poland
Kretowski, A. J., Kowalska, I., Peczyńska, J., Urban, M., Green, A., & Kinalska, I. (2001) · Diabetologia · doi:10.1007/pl00002954 · Cited by 22
Cited by
Hod, M., Kapur, A., Sacks, D. A., Hadar, E., Agarwal, M., Di Renzo, G. C., Roura, L. C., McIntyre, H. D., Morris, J. L., & Divakar, H. (2015) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(15)30033-3 · Cited by 767
Proceedings of the 2004 Winter Simulation Conference, 2004.
(2004) · doi:10.1109/wsc.2004 · Cited by 587
A Review of Diabetes Treatment Adherence and the Association with Clinical and Economic Outcomes
Asche, C., LaFleur, J., & Conner, C. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.01.019 · Cited by 420
Cummins, E., Royle, P., Snaith, A., Greene, A., Robertson, L., McIntyre, L., & Waugh, N. (2010) · Health Technology Assessment · doi:10.3310/hta14110 · Cited by 335
Validation of the CORE Diabetes Model Against Epidemiological and Clinical Studies
Palmera, A. J., Rozea, S., Valentinea, W. J., Minshallb, M. E., Foosa, V., Luratia, F. M., Lammerta, M., & Spinasc, G. A. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904x2006 · Cited by 284
Metadata
- Authors
- Palmer, A. J., Roze, S., Valentine, W. J., Minshall, M. E., Foos, V., Lurati, F. M., Lammert, M., & Spinas, G. A.
- Venue
- Current Medical Research and Opinion
- Publisher
- Informa UK Limited
- Published
- 2004-01
- Volume
- 20
- Issue
- sup1
- Pages
- S5-26
- ISSN
- 0300-7995 (ISSN-L)
- 1473-4877
- OpenAlex
- W2169355652
- Cited by
- 526
- References
- 93
- FWCI
- 39.51
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.